Transfusional iron burden and liver toxicity after bone marrow transplantation for acute myelogenous leukemia and hemoglobinopathies

Pediatric Blood and Cancer

Volumn 50, Issue 2, 2008, Pages 319-324

  Jastaniah, Wasil ^a,b,e   Harmatz, Paul ^c   Pakbaz, Zahra ^c   Fischer, Roland ^c,d   Vichinsky, Elliott ^c   Walters, Mark C ^c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UMM AL QURA UNIVERSITY   (Saudi Arabia)

^c CHILDREN S HOSPITAL OAKLAND   (United States)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e NONE   (Canada)

Author keywords

Bone marrow transplant; Iron overload; Phlebotomy; Transfusion; Veno occlussive disease; VOD

Indexed keywords

ALANINE AMINOTRANSFERASE; BIOLOGICAL MARKER; FERRITIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ARTICLE; BONE MARROW TRANSPLANTATION; CHILD; CLINICAL ARTICLE; CONCENTRATION RESPONSE; ERYTHROCYTE; ERYTHROCYTE TRANSFUSION; ERYTHROCYTE VOLUME; FEMALE; HEMATOLOGIC MALIGNANCY; HEMOGLOBINOPATHY; HEPATITIS; HLA SYSTEM; HUMAN; IRON OVERLOAD; LIVER FIBROSIS; LIVER HISTOLOGY; LIVER TOXICITY; MALE; PHLEBOTOMY; PRIORITY JOURNAL; SICKLE CELL ANEMIA; TIME SERIES ANALYSIS; TRANSFUSION; VEIN OCCLUSION;

ADOLESCENT; ANEMIA, SICKLE CELL; BETA-THALASSEMIA; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IRON; IRON OVERLOAD; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LIVER; LIVER DISEASES; LONGITUDINAL STUDIES; MALE; RETROSPECTIVE STUDIES;

EID: 37549069928     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21260     Document Type: Article

References (25)

1. Muretto P, Del Fiasco S, Angelucci E, et al. Bone marrow transplant in thalassemia: Modifications of hepatic iron overload and associated lesions after long-term engrafting. Liver 1994;14:14-24.
2. Angelucci E, Muretto P, Lucarelli G, et al. Phlebotomy to reduce iron overload in patients cured of thalassemia by bone marrow transplantation. Italian Cooperative Group for phlebotomy treatment of transplanted thalassemia patients. Blood 1997;90:994-998.
3. Angelucci E, Muretto P, Nicolucci A, et al. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood 2002;100:17-21.
4. Angelucci E, Brittenham GM, McLaren CE, et al. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med 2000;343:327-331.
5. Barry M. Liver iron concentration, stainable iron, and total body storage iron. Gut 1974;15:411-415.
6. Valberg LS, Simon JB, Manley PN, et al. Distribution of storage iron as body stores expand in patients with hemochromatosis. J Lab Clin Med 1975;86:479-489.
7. Harmatz P, Butensky E, Quirolo K, et al. Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy. Blood 2000;96:76-79.
8. Muretto P, Angelucci E, Lucarelli G. Reversibility of cirrhosis in patients cured of thalassemia by bone marrow transplantation. Ann Intern Med 2002;136:667-672.
9. Ware RE, Zimmerman SA, Sylvestre PB, et al. Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy. J Pediatr 2004;145:346-352.
10. Fischer R, Tiemann CD, Engelhardt R, et al. Assessment of iron stores in children with transfusion siderosis by biomagnetic liver susceptometry. Am J Hematol 1999;60:289-299.
11. Brittenham GM, Farrell DE, Harris JW, et al. Magnetic-susceptibility measurement of human iron stores. N Engl J Med 1982;307:1671-1675.
12. Fischer R, Harmatz P, Nielsen P. Does liver biopsy overestimate liver iron concentration? Blood 2006;108:1775-1776.
13. Fischer R, Piga A, Harmatz P, et al. Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry. Ann NY Acad Sci 2005;1054:350-357.
14. Lord E. The use of the range in place of standard deviation in the t-test. Biometrika 1947;34:41-67.
15. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997;89:739-761.
16. Brittenham GM, Cohen AR, McLaren CE, et al. Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major. Am J Hematol 1993;42:81-85.
17. Worwood M, Cragg SJ, Jacobs A, et al. Binding of serum ferritin to concovalin A: Patients with homozygous beta thalassemia and transfusional iron overload. Br J Haematol 1980;4:410-416.
18. Telfer PT, Prestcott E, Holden S, et al. Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassemia major. Br J Haematol 2000;110:971-977.
19. Gungor T, Rohrbach E, Solem E, et al. Logarithmic quantitation model using serum ferritin to estimate iron overload in secondary hemochromatosis. Arch Dis Child 1996;74:323-327.
20. Carreras E, Bertz H, Arcese W, et al. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: A prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia working party. Blood 1998;92:3599-3604.
21. Poonkuzhali B, Srivastava A, Quernin MH, et al. Pharmacokinetics of oral busulphan in children with beta thalassemia major undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant 1999;24:5-11.
22. Li CK, Yuen PM, Wong R, et al. Busulphan level and early mortality in thalassemia patients after BMT Bone Marrow Transplant 1999;23:307-310.
23. Tomaro ML, Battle AM. Bilirubin: Its role in cytoprotection against oxidative stress. Int J Biochem Cell Biol 2002;34:216-220.
24. Deugnier YM, Loreal O, Turlin B, et al. Liver pathology in genetic hemochromatosis: A review of 135 cases and their bioclinical correlations. Gastroenterology 1992;102:2050-2059.
25. Batts KP, Ludwig J. Chronic Hepatitis. An update on terminology and reporting. Am J Surg Pathol 1995;19:1409-1417.